Analysis of intratumoral immune response early on Nivolumab treatment in unresectable advanced or recurrent gastric cancer.
Phase of Trial: Phase IV
Latest Information Update: 07 Dec 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 27 Nov 2017 Status changed from not yet recruiting to recruiting.
- 20 Oct 2017 New trial record